Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 5, 2025
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecanHope Rugo, Aditya Bardia, Debora S Bruno, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Gynecologic Oncology|July 2, 2025
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIOMelissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
Nature Cancer|July 5, 2022
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancerLaura M Spring, Hyo Han, Minetta C Liu, et al.
Breast Cancer Research : BCR|December 3, 2011
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastasesBarbara Adamo, Allison M Deal, Emily Burrows, et al.
Clinical Breast Cancer|November 5, 2020
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast CancerErika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast CancerTimothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
Gynecologic Oncology|June 11, 2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumabMelissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Pageof 9